ClinicalTrials.gg
CompletedNCT00233064Updated Jun 27, 2018Results posted

Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)

A Phase 4 interventional study of Lyophilized Palivizumab and Liquid Palivizumab in Chronic Lung Disease, sponsored by MedImmune LLC. Completed at 54 sites in United States. Open to participants aged Up to 24 Months. Per ClinicalTrials.gov, last updated 2018-06-27.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
417
Allocation
Randomized
Ages
Up to 24 Months
Sex
All
01

Study summary

The purpose of this study is to measure the rate of anti-palivizumab antibodies (also referred to as immune reactivity or immunogenicity) in subjects receiving either the liquid or lyophilized formulation of palivizumab. This study will compare the number and percentage of subjects with anti-palivizumab antibodies receiving either the liquid or lyophilized formulation of palivizumab.

Read the detailed description

The approved liquid formulation of palivizumab was developed to simplify preparation of the drug before injection. Both formulations of palivizumab have been shown to be bioequivalent in children 6 months of age or younger with a history of chronic lung disease. In previous studies of liquid palivizumab, immunogenicity was evaluated up to 2 months after dosing in adults, and 1 month after dosing in children. In this study, MI-CP116, immunogenicity will be evaluated between 4 and 6 months after the last dose of study drug, in order to provide data at a time point significantly distant from dosing when drug interference is minimal.

02

Conditions studied

  • Chronic Lung Disease
03

In context

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted before MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically stable child with chronic lung disease of prematurity who is ≤24 months of age at randomization OR child with premature birth (gestational age ≤35 weeks or less) and who is 6 months of age or younger at randomization
  • Written obtained from the patient's parent(s) or legal guardian(s)
  • The child must be able to complete the follow-up visit 4-6 months after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Hospitalization at the time of randomization (unless discharge is anticipated within 3 weeks)
  • Be receiving mechanical ventilation at the time of study entry (including CPAP)
  • Congenital heart disease (children with uncomplicated CHD [e.g., PDA, small septal defect] and children with complicated CHD who are currently anatomically and hemodynamically normal can be enrolled).
  • Mother with infection (unless the child has been proven to be not infected)
  • \<6 months
  • Known allergy to Ig products
  • Acute respiratory or other acute infection or illness
  • Previous reaction to IGIV, blood products, or other foreign proteins
  • Receipt of lyophilized palivizumab, RSV-IG IV, or other RSV-specific monoclonal antibody, or any other polyclonal antibody (for example, IG, IVIG, VZIG) within 3 months prior to randomization
  • Any previous receipt of MEDI-524
  • Participation in other drug product studies
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
417 participants (actual)

Study arms

  • Active comparator
    1

    Liquid Palivizumab

    Biological: Liquid Palivizumab

  • Active comparator
    2

    Lyophilized Palivizumab

    Biological: Lyophilized Palivizumab

Interventions

  • Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.

    Also known as: Synagis

  • Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.

    Also known as: Synagis

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants With Immune Reactivity

    Presence of anti-palivizumab antibodies

    Time frame: Day 240-300 follow up

07

Results

Posted Oct 28, 2008
Limitations and caveats
Only serious adverse events were collected as part of the safety evaluation. One death (asphyxia) occurred in the Lyophilized Palivizumab group; this event was judged not related to study drug.

Participant flow

A total of 417 subjects were randomized into the study at 51 sites in the United States between 20 October 2005 and 02 October 2007.

Participant flow — Overall Study
MilestoneLiquid PalivizumabLyophilized Palivizumab
Started211202
Completed197190
Not completed1412
Withdrew: Lost to follow-up77
Withdrew: Withdrawal by subject53
Withdrew: Death01
Withdrew: Relocation01
Withdrew: Protocol violation10
Withdrew: Moved to dom. republic10

Outcome measures

PrimaryNumber and Percentage of Participants With Immune Reactivity

Presence of anti-palivizumab antibodies

Time frame:
Day 240-300 follow up
Reported as:
Number · Participants
Number and Percentage of Participants With Immune Reactivity
ParticipantsLiquid PalivizumabLyophilized PalivizumabCombined Liquid/Lyophilized Palivizumab
Number011
Percentage0.00.50.3
Statistical analysis
  • Liquid Palivizumab · Overall percentage of immune reactivity: 0.0 · 95% CI 0.0 to 1.9The number and percentage of subjects with immune reactivity at Study Day 240-300 were constructed using the Clopper-Pearson Method.
  • Lyophilized Palivizumab · Overall percentage of immune reactivity: 0.5 · 95% CI 0.0 to 2.9The number and percentage of subjects with immune reactivity at Study Day 240-300 were constructed using the Clopper-Pearson Method.
  • Combined Liquid/Lyophilized Palivizumab · Overall percentage of immune reactivity: 0.3 · 95% CI 0.0 to 1.5The number and percentage of subjects with immune reactivity at Study Day 240-300 were constructed using the Clopper-Pearson Method.

Adverse events

Collected over Serious adverse events were collected from the time of the first study drug administration through Study Day 150. Adverse events were not collected in this study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liquid Palivizumab—18/211 (8.5%)0/211 (0%)
Lyophilized Palivizumab—12/202 (5.9%)0/202 (0%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventLiquid PalivizumabLyophilized Palivizumab
BronchiolitisInfections and infestations6/2113/202
GastroenteritisInfections and infestations2/2112/202
Respiratory DistressRespiratory, thoracic and mediastinal disorders0/2112/202
Viral InfectionInfections and infestations2/2110/202
Cleft LipCongenital, familial and genetic disorders1/2111/202
Inguinal HerniaGastrointestinal disorders1/2111/202
AbscessInfections and infestations0/2111/202
Occult Blood PositiveGastrointestinal disorders0/2111/202
Failure to ThriveMetabolism and nutrition disorders0/2111/202
ApnoeaRespiratory, thoracic and mediastinal disorders0/2111/202

Baseline characteristics

Age, Continuous
Age, Continuous(months)Liquid PalivizumabLyophilized PalivizumabTotal
Mean4.56 ± 4.504.00 ± 4.164.29 ± 4.34
Sex: Female, Male
Sex: Female, Male(Participants)Liquid PalivizumabLyophilized PalivizumabTotal
Female10499203
Male107103210
Region of Enrollment
Region of Enrollment(participants)Liquid PalivizumabLyophilized PalivizumabTotal
United States211202413
Chronic Lung Disease at Prematurity
Chronic Lung Disease at Prematurity(Participants)Liquid PalivizumabLyophilized PalivizumabTotal
Yes352661
No176176352
Race/Ethnicity
Race/Ethnicity(Participants)Liquid PalivizumabLyophilized PalivizumabTotal
American Indian or Alaska Native000
Asian134
Native Hawaiian or Other Pacific Islander000
Black or African American252449
White151149300
More than one race000
Unknown or Not Reported000
Hispanic221436
Other121224
Gestational Age at Birth
Gestational Age at Birth(Weeks)Liquid PalivizumabLyophilized PalivizumabTotal
Mean32.4 ± 2.732.7 ± 2.532.5 ± 2.6
Weight at Day 0
Weight at Day 0(Kilogram)Liquid PalivizumabLyophilized PalivizumabTotal
Mean5.326 ± 2.2745.079 ± 2.2645.205 ± 2.270
08

Study locations

54 sites
  • Birmingham Pediatric Associates
    Birmingham, Alabama 35235, United States
  • Clinical Research Consultants
    Hoover, Alabama 35216, United States
  • The University of Alabama School of Medicine
    Tuscaloosa, Alabama 35487, United States
  • All for Kids Pediatric Clinic
    Little Rock, Arkansas 72211, United States
  • Family Medical Center
    Foothill Ranch, California 92610, United States
  • Edinger Medical Group
    Fountain Valley, California 92708, United States
  • Doctors Medical Group
    West Covina, California 91790, United States
  • Convenience Care
    West Covina, California 91791, United States
  • Norwich Pediatric Group, P.C.
    Norwich, Connecticut 06360, United States
  • The Allergy Center at Brookstone
    Columbus, Georgia 31904, United States
  • Physicians to Children and Adolescents
    Bardstown, Kentucky 40004, United States
  • Peak Medical Research LLC
    Owensboro, Kentucky 42303, United States
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
  • Pediatric Association of Fall River
    Fall River, Massachusetts 02724, United States
  • Woburn Pediatric Associates
    Woburn, Massachusetts 01801, United States
  • Michigan Institute of Medicine
    Livonia, Michigan 41852, United States
  • Meridian Clinical Research
    Omaha, Nebraska 68134, United States
  • St. Joseph's Childrens Hospital
    Paterson, New Jersey 07503, United States
  • Maimonides Pediatric Pulmonology
    Brooklyn, New York 11230, United States
  • North Carolina Children's & Adult's Clinical Research Foundation/Purcell Clinic
    Laurinburg, North Carolina 28352, United States
  • Capitol Pediatric And Adolescent Center
    Raleigh, North Carolina 27609, United States
  • North Carolina Children's and Adult's Clinical Research Foundation
    Sylva, North Carolina 28779, United States
  • Medcenter One/Q&R Clinic
    Bismarck, North Dakota 58501, United States
  • Dakota Clinic, Ltd. / Innvois Health
    Fargo, North Dakota 58103, United States
  • Trinity Medical Group-Health Center Medical Arts
    Minot, North Dakota 58701, United States
  • Dr. Shelly David Senders, M.D., Inc.
    Cleveland, Ohio 44118, United States
  • Northeast Cincinnati Pediatric Associates, Inc
    Mason, Ohio 45040, United States
  • Santiago Reyes, M.D.
    Oklahoma City, Oklahoma 73112, United States
  • Tri-State Pediatrics
    Beaver Falls, Pennsylvania 15010, United States
  • Greenville Medical Center
    Greenville, Pennsylvania 16125, United States
  • CCP - Armstrong Pediatrics
    Kittanning, Pennsylvania 16201, United States
  • Pediatric Alliance of Latrobe
    Latrobe, Pennsylvania 15650, United States
  • Temple Univ. Children's Medical Center
    Philadelphia, Pennsylvania 19140, United States
  • Pediatric Alliance, Southwestern
    Pittsburgh, Pennsylvania 15217, United States
  • South Hills Pediatrics
    Pittsburgh, Pennsylvania 15227, United States
  • Pediatric Alliance, Southwestern
    Pittsburgh, Pennsylvania 15236, United States
  • Primary Physician's Research, Inc.
    Pittsburgh, Pennsylvania 15241, United States
  • Laurel Pediatrics
    Uniontown, Pennsylvania 15401, United States
  • Brown Clinic P.L.L.P./Northridge Clinic
    Watertown, South Dakota 57201, United States
  • Jackson Clinic
    Jackson, Tennessee 38305, United States
  • Holston Medical Group; Pediatrics at Meadowview Lane
    Kingsport, Tennessee 37660, United States
  • Holston Medical Group; Pediatrics at Stone Plaza
    Kingsport, Tennessee 37660, United States
  • Sadler Clinic
    Conroe, Texas 77304, United States
  • Pediatric Allergy/Immunology Associates, PA
    Dallas, Texas 75230, United States
  • MedPro Research
    Houston, Texas 77004, United States
  • Pediatric Associates
    Houston, Texas 77087, United States
  • Quality Assurance Research Center
    San Antonio, Texas 78205, United States
  • Wee Care Pediatrics
    Layton, Utah 84041, United States
  • Bear Care Pediatrics
    Ogden, Utah 84405, United States
  • Utah Valley Pediatrics
    Provo, Utah 84604, United States
  • Families First Pediatrics
    South Jordan, Utah 84095, United States
  • Advanced Pediatrics
    Vienna, Virginia 22180, United States
  • WVU Department of Pediatrics
    Charleston, West Virginia 25202, United States
  • Monroe Clinic
    Monroe, Wisconsin 53566, United States
09

References and documents

Publications

  • Makari D, Jensen KM, Harris B, Jafri HS. Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity. Infect Dis Ther. 2014 Dec;3(2):339-47. doi: 10.1007/s40121-014-0033-y. Epub 2014 Aug 26. PubMed 25156956 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Oct 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2008, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2005
First posted
Oct 5, 2005
Start
Oct 2005
Primary completionActual
Oct 2007
CompletionActual
Nov 2007
Results first posted
Oct 28, 2008
Last update
Jun 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00233064
Lead sponsor
MedImmune LLC
First posted
Oct 5, 2005
Start date
Oct 2005
Primary completion
Oct 2007
Completion
Nov 2007
Results posted
Oct 28, 2008
Last update
Jun 27, 2018

Study contacts

Genny Losonsky, MD
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palivizumab

Start the discussion